Aradigm Corporation Selects Pulmaquin™ for Phase 3 Development and Announces Issuance of its First U.S. Patent Covering Inhaled Ciprofloxacin Formulations

Published: Dec 07, 2011

HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTCBB:ARDM) ("Aradigm" or the “Company”) today announced that the United States Patent and Trademark Office has issued an important patent (U.S. Patent No. 8,071,127) regarding formulations of inhaled liposomal and free ciprofloxacin including its lead preparation, Pulmaquin™ (Dual Release Ciprofloxacin for Inhalation, DRCFI, ARD-3150). The Company expects that the patent will provide exclusivity for Pulmaquin until October 22, 2027.

Back to news